Head to head
Johnson & Johnson vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: JNJ · LLY
JNJ
Johnson & Johnson
261.44+1.93%
1-year price shape — +40% over the period
Quant Rating B · 78/100
vs
LLY
Eli Lilly and Co
1,179.27+0.83%
1-year price shape — +39% over the period
Quant Rating B · 77/100
1-year performance, rebased to 100
Johnson & Johnson edges it on the scoreable measures. Johnson & Johnson has the highest Quant Rating (78); Johnson & Johnson has done best over the past year (+40%); Johnson & Johnson trades cheapest on trailing earnings.
| JNJ | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Drug Manufacturers - General |
| Last price | 261.44 | 1,179.27 |
| Change today | +1.93% | +0.83% |
| 1-year return | +39.9% | +38.7% |
| Market cap | $630.04B | $1.11T |
| 52-week range | 180.59 – 281.07 | 778.93 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 30.33 | 39.59 |
| P/E percentile, own 5-yr range | 85th | 6th |
| P/B | 7.41 | 32.77 |
| Dividend yield | 2.00% | 0.55% |
| Profitability & growth | ||
| EPS (TTM) | 11.03 | 22.95 |
| Net profit (TTM) | $26.58B | $21.60B |
| Revenue (TTM) | $97.93B | $79.67B |
| Revenue growth (YoY) | +6.6% | +47.7% |
| Gross margin | 67.9% | 83.4% |
| Operating margin | 26.8% | 49.7% |
| Net margin | 21.5% | 33.5% |
| Free cash flow (TTM) | $22.23B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 76.4% | 79.3% |
| Insider activity (12mo) | 27 buy / 20 sell | 37 buy / 13 sell |
| Short interest (% of float) | 0.9% | 0.7% |
| Analyst consensus | 78% buy / 22% hold (18) | 91% buy / 5% hold / 5% sell (22) |
| Analyst price target | $290 (+11%) | $1,383 (+17%) |
| StockVane view | ||
| StockVane Quant Rating | B (78) | B (77) |
| Company | ||
| Employees | 138,200 | 50,000 |
| Founded | 1887 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.